摘要
目的:探讨IL-6能否作为一种新的肿瘤标记物用于卵巢上皮性癌早期诊断及卵巢良、恶性肿瘤鉴别诊断;通过动态观察卵巢癌治疗前后IL-6值的变化,观察它在疗效监测中的意义;探讨联合检测IL-6与CA125在卵巢癌早期诊断及疗效监测中的意义。方法:以原发性卵巢上皮癌患者30例为研究组,卵巢良性肿瘤、正常妇女、子宫内膜异位症、其它妇科恶性肿瘤共40例为对照组,检测研究组术前、1-4次化疗后,正常妇女研究前、其他卵巢良性肿瘤及子宫内膜异位症组治疗前、其他妇科恶性肿瘤组手术前、后血清IL-6水平及CA125水平,分析探讨IL-6作为肿瘤标记物在卵巢癌诊治中的意义。结果:卵巢癌患者IL-6血清值术前明显高于对照组(P<0.01),术后及化疗后逐渐降低(P<0.05);血清IL-6、CA125联合检测,可提高卵巢癌早期诊断的敏感性(P<0.05)。结论:IL-6是早期诊断卵巢癌和评估预后的可靠指标,联合CA125检测可以提高卵巢癌的早期诊断率。
Objective:To investigate the possibility with IL-6 as a new tumor marker for early diagnosis and differential diagnosis of ovarian cancer or benign tumor;to observe the significance of the variation before and after treatment of IL-6;to study the significance of simultaneous determination with IL-6 and CA125 for early diagnosing and monitoring of curative effect of ovarian cancer.Method:The study group was the patients(n=30) with idiopathic epithelial ovarian cancer,the control group was the patients(n=40) with ovarian benign tumor,normal female,endometriosis and other gynecological malignant tumor,serum IL-6 and CA125 levels were determined in the study group and other gynecological malignant tumor group perioperatively and post-chemotherapy from the first to the fourth time,serum IL-6 and CA125 levels were also determined in normal before research,other ovarian benign tumor group and endometriosis group perioperatively,as to investigate the significance in diagnosis and treatment of ovarian cancer with IL-6 as a new tumor marker.Result:Serum IL-6 levels in the study group were significantly higher than those in the control group(P〈0.01),and serum IL-6 levels were gradually decreased in the study group at postoperation and post-chemotherapy(P〈0.05);the sensitivity for early diagnosis of ovarian cancer were increased with simultaneous determination with IL-6 and CA125(P〈0.05).Conclusion:Serum IL-6 levels can be used for early diagnosis and prognostic evaluation of ovarian cancer as a reliable indicator,the early diagnosis rate of ovarian cancer can be increased with simultaneous determination with IL-6 and CA125.
出处
《河北医学》
CAS
2011年第6期751-754,共4页
Hebei Medicine
基金
广东省深圳市科技和信息局立项课题(项目编号:200803010)